Oct 2026· Statistics in Medicine· Vol 45· 0 citations· 62 references
Medicine
TL;DR
Two recently developed methods for subgroup selection in regression problems are discussed: one based on generalized linear modeling and another on isotonic regression, focusing on two distinct tasks: identifying patient groups that are safe from manifesting adverse events and identifying patient groups with high treatment effect, while controlling for Type I error in both cases.
Abstract
Subgroup selection in clinical trials is essential for identifying patient groups that react differently to a treatment, thereby enabling personalized medicine. In particular, subgroup selection can identify patient groups that respond particularly well to a treatment or that encounter adverse events more often. However, this is a post‐selection inference problem, which may pose challenges for traditional techniques used for subgroup analysis, such as increased Type I error rates and potential biases from data‐driven subgroup identification. In this paper, we discuss two recently developed methods for subgroup selection in regression problems: one based on generalized linear modeling and another on isotonic regression. We demonstrate how these methods can be used for data‐driven subgroup identification in the analysis of clinical trials, focusing on two distinct tasks: identifying patient groups that are safe from manifesting adverse events and identifying patient groups with high treatment effect, while controlling for Type I error in both cases. A thorough simulation study is conducted to evaluate the strengths and weaknesses of each method, providing detailed insight into the sensitivity of the Type I error rate control to modeling assumptions.
Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related...
J. Efird, Genevieve N. Dupuis, Yuk-Ming Choi et al.· International Journal of Env...· 0 citations
In crossover designs, multiple outcomes are often collected to assess treatment effectiveness in a comprehensive manner. Also, interest has grown in comparing intra‐subject variability between treatments in such designs. We present three distinct multivariate linear mixed‐effects models, with the choice of the model de...
Yi Jiang, V. Chinchilli· Biometrical journal. Biometr...· 0 citations
When the number of patients is limited in clinical trials for rare diseases and pediatric developments, enrolling sufficient participants for confirmatory randomized clinical trials is difficult. Alternative trial designs using external controls have been proposed: augmented randomized clinical trials (ARCTs) and suppl...
K. Kudo, Tosiya Sato· Pharmaceutical statistics· 0 citations
A unified perspective in which heterogeneous analysis is a problem of structured information borrowing is developed, with an agenda for calibrated personalization that integrates multilevel representations, selective borrowing, subgroup-aware evaluation, and valid uncertainty quantification.
Xuan Bi, Spencer Hilligoss, C. Pinkerton et al.· 0 citations
Data-driven subgroup identification is increasingly used in clinical trials, yet the effect reported for a discovered subgroup is typically the standard analysis: a Cox or generalized-linear-model treatment coefficient fitted within that subgroup. Selection by an effect-driven rule --- rewarding large estimated effects...
Multivariate endpoints are increasingly used in clinical studies on rare diseases, where sample sizes tend to be small and distributional assumptions are often violated. In such settings, commonly applied parametric multivariate methods, such as classical MANOVA approaches, may suffer from inflated type‐I error or redu...
Martin Geroldinger, M. Laimer, V. Wally et al.· Statistics in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.